630 related articles for article (PubMed ID: 27756786)
1. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
Sayyid RK; Evans A; Hersey K; Maloni R; Hurtado-Coll A; Kulkarni G; Finelli A; Zlotta AR; Hamilton R; Gleave M; Fleshner NE
Clin Cancer Res; 2017 Apr; 23(8):1974-1980. PubMed ID: 27756786
[No Abstract] [Full Text] [Related]
2. Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.
Axcrona K; Aaltomaa S; da Silva CM; Ozen H; Damber JE; Tankó LB; Colli E; Klarskov P
BJU Int; 2012 Dec; 110(11):1721-8. PubMed ID: 22500884
[TBL] [Abstract][Full Text] [Related]
3. Degarelix Versus Goserelin Plus Bicalutamide in the Short-Term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis.
Mason M; Richaud P; Bosnyak Z; Malmberg A; Neijber A
Low Urin Tract Symptoms; 2017 May; 9(2):82-88. PubMed ID: 28394498
[TBL] [Abstract][Full Text] [Related]
4. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
5. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.
Mason M; Maldonado Pijoan X; Steidle C; Guerif S; Wiegel T; van der Meulen E; Bergqvist PB; Khoo V
Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):190-6. PubMed ID: 23257248
[TBL] [Abstract][Full Text] [Related]
7. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
8. Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients.
Usami M; Akaza H; Arai Y; Hirano Y; Kagawa S; Kanetake H; Naito S; Sumiyoshi Y; Takimoto Y; Terai A; Yoshida H; Ohashi Y
Prostate Cancer Prostatic Dis; 2007; 10(2):194-201. PubMed ID: 17199134
[TBL] [Abstract][Full Text] [Related]
9. Chemical castration and anti-androgens induce differential gene expression in prostate cancer.
Lehmusvaara S; Erkkilä T; Urbanucci A; Waltering K; Seppälä J; Larjo A; Tuominen VJ; Isola J; Kujala P; Lähdesmäki H; Kaipia A; Tammela TLj; Visakorpi T
J Pathol; 2012 Jul; 227(3):336-45. PubMed ID: 22431170
[TBL] [Abstract][Full Text] [Related]
10. Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
Schellhammer P; Sharifi R; Block N; Soloway M; Venner P; Patterson AL; Sarosdy M; Vogelzang N; Jones J; Kolvenbag G
Urology; 1996 Jan; 47(1A Suppl):54-60; discussion 80-4. PubMed ID: 8560679
[TBL] [Abstract][Full Text] [Related]
11. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
13. Metabolic changes with degarelix vs leuprolide plus bicalutamide in patients with prostate cancer: a randomized clinical study.
Sawazaki H; Araki D; Kitamura Y; Yagi K
World J Urol; 2020 Jun; 38(6):1465-1471. PubMed ID: 31482294
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
[TBL] [Abstract][Full Text] [Related]
15. Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.
Cui Y; Zong H; Yan H; Li N; Zhang Y
Urol Int; 2014; 93(2):152-9. PubMed ID: 24603064
[TBL] [Abstract][Full Text] [Related]
16. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists.
Klotz L; Miller K; Crawford ED; Shore N; Tombal B; Karup C; Malmberg A; Persson BE
Eur Urol; 2014 Dec; 66(6):1101-8. PubMed ID: 24440304
[TBL] [Abstract][Full Text] [Related]
17. [Intermittent androgen deprivation treatment of prostate cancer restarted at low level of serum prostate specific antigen: a pilot study].
Maekawa S; Maegawa M; Ushida H; Inoue K; Kaneko Y; Ohmori K; Nishimura K
Hinyokika Kiyo; 2001 Aug; 47(8):553-5. PubMed ID: 11579594
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group.
Schellhammer PF; Sharifi R; Block NL; Soloway MS; Venner PM; Patterson AL; Sarosdy MF; Vogelzang NJ; Schellenger JJ; Kolvenbag GJ
Urology; 1997 Sep; 50(3):330-6. PubMed ID: 9301693
[TBL] [Abstract][Full Text] [Related]
19. Degarelix: a new approach for the treatment of prostate cancer.
Persson BE; Kold Olesen T; Jensen JK
Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
[TBL] [Abstract][Full Text] [Related]
20. Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
Koh Y; Kawashima A; Ujike T; Nagahara A; Fujita K; Kiuchi H; Imamura R; Miyagawa Y; Nonomura N; Uemura M
Anticancer Drugs; 2020 Nov; 31(10):1099-1102. PubMed ID: 32804697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
